Replies to post #81214 on Biotech Values

[DewDiligence]

IDIX re: Potential up-front license fee for IDX184

Caris & Co. analyst David Moskowitz reaffirmed a "Buy" rating on the stock and expects shares to reach $16 over the next 52 weeks. He said IDX-184's safety profile and better potency than a prior drug candidate will prompt Novartis to opt into the drug's development. That could result in an upfront payment of $25 million, he said, along with development funding.

I decided to do some DD to ascertain how reasonable (or unreasonable) Moskowitz’s $25M figure is. Please see the table in the next post.